

LunairCF is a Phase 2 open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators. **NCT: 06747858**

STUDY OVERVIEW



PURPOSE

To evaluate the safety and tolerability of ARCT-032 in adults with CF, including those with mutations that do not respond to CFTR modulators and those who did not tolerate or respond well to CFTR modulators in the past.



TREATMENT

There is no placebo for this study. Participants will receive doses of ARCT-032 via inhalation for 28 days.



DURATION

There will be approximately 8 study visits, and 2 follow-up phone calls over a 16-week period (including screening visit).



LOCATION

There will be approximately 20+ sites in the US, Europe and the Middle East.

What is ARCT-032?

ARCT-032 is an investigational inhaled messenger RNA (mRNA) treatment designed to treat the root cause of Cystic Fibrosis. It aims to deliver a normal copy of the Cystic Fibrosis Transmembrane Conductance Regulator (*CFTR*) gene to lung cells using a delivery system developed by Arcturus known as LUNAR[®]. Lung cells then use the instructions in the mRNA to create functional CFTR protein.

Who can participate?

- Adults 18 years of age or older with confirmed diagnosis of Cystic Fibrosis
- Not eligible for CFTR modulators therapy or not taking CFTR modulators
- Forced expiratory volume in 1 second (FEV1) between 40% to 100% of predicted values at screening
- Other requirements may apply

Those who qualify will receive all study-related laboratory tests, medical exams, and travel at no cost.

Scan the QR code to learn more about the **LunairCF** study or visit [ClinicalTrials.gov NCT06747858](https://ClinicalTrials.gov/NCT06747858)

For all other questions, please contact us directly CFClinicalTrials@ArcturusRx.com

